Aspivix key facts
- Developer of a suction cervical stabilizer designed to reduce pain and eliminate the risk of lesions and bleeding in women for gynecological purposes.
- Aspivix’s last known valuation is $28.4M.
- It has raised $20.1M; the latest was Equity Crowdfunding ($2.8M) in Mar 2025.
- Notable investors include MassChallenge, Venture Kick, Innosuisse, Zürcher Kantonalbank, 4FOX Ventures — 11 tracked in total.
- Status: Privately Held (backing).
Who backs Aspivix
11+- ·The complete investor list: 11 names
- ·Watch Aspivix: the Monday email on marks, rounds and moves
Aspivix funding rounds
No funding rounds for Aspivix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Aspivix valuation
Aspivix's last known valuation is $28.4 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Aspivix investors
11 investors are on record for Aspivix, including MassChallenge, Venture Kick, Innosuisse and Zürcher Kantonalbank.
About Aspivix
Developer of a suction cervical stabilizer designed to reduce pain and eliminate the risk of lesions and bleeding in women for gynecological purposes. The company's device is based on a patented suction pad technology that facilitates the gentle handling of cervix pain during gynecological procedures, enabling physicians to avoid normal bleeding, cervical tears, and lacerations, protecting patients from the risk of developing cross-infections.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2015
- Employees
- 9
- Website
- aspivix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Aspivix’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.